Cartesian Therapeutics, Inc. - Understand $rnac stock

$RNAC Market Cap: $559.1 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$47.94M

TTM

Gross Margin

Net Earnings

-$244.8M

TTM

Current Assets

$229.1M

Q3 2024

Current Liabilities

$21.41M

Q3 2024

Current Ratio

1070.48%

Q3 2024

Total Assets

$455.3M

Q3 2024

Total Liabilities

$454.6M

Q3 2024

Book Value

$752.0K

Q3 2024

Cash

$219.2M

Q3 2024

P/E

-2.284

Nov 29, 2024 EST

Free Cash Flow

-$48.41M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	$26.00M	$110.8M	$85.08M	$16.60M	$6.677M	$903.0K	$207.0K	$8.083M	$6.011M	$3.040M
YoY Change	-76.53%	30.21%	412.6%	148.57%	639.42%	336.23%	-97.44%	34.47%	97.73%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	$26.00M	$110.8M	$85.08M	$16.60M	$6.677M	$903.0K	$207.0K	$8.083M	$6.011M	$3.040M
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Selling, General & Admin	$40.48M	$23.86M	$20.94M	$18.91M	$16.39M	$18.24M	$18.83M	$13.05M	$8.340M	$7.950M
YoY Change	69.65%	13.97%	10.72%	15.38%	-10.14%	-3.13%	44.29%	56.47%	4.91%
% of Gross Profit
Research & Development	$71.84M	$72.38M	$68.74M	$54.51M	$42.74M	$47.69M	$45.17M	$29.70M	$22.98M	$10.49M
YoY Change	-0.74%	5.3%	26.11%	27.52%	-10.37%	5.58%	52.06%	29.25%	119.15%
% of Gross Profit
Depreciation & Amortization	$700.0K	$700.0K	$600.0K	$600.0K	$700.0K	$1.000M	$800.0K	$800.0K	$1.044M	$864.0K
YoY Change	0.0%	16.67%	0.0%	-14.29%	-30.0%	25.0%	0.0%	-23.37%	20.83%
% of Gross Profit
Operating Expenses	$112.4M	$96.24M	$89.67M	$73.42M	$59.13M	$65.93M	$63.99M	$42.75M	$31.32M	$18.44M
YoY Change	16.81%	7.32%	22.14%	24.16%	-10.3%	3.02%	49.68%	36.53%	69.83%
Operating Profit	-$86.42M	$14.54M	-$4.597M	-$56.82M	-$52.46M	-$65.02M	-$63.78M	-$34.67M	-$25.30M	-$15.40M
YoY Change	-694.41%	-416.25%	-91.91%	8.32%	-19.33%	1.94%	83.97%	37.01%	64.32%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Interest Expense	$2.833M	$3.031M	$2.844M	$1.556M	$1.519M	$1.494M	$1.206M	$1.253M	$948.0K	$552.0K
YoY Change	-6.53%	6.58%	82.78%	2.44%	1.67%	23.88%	-3.75%	32.17%	71.74%
% of Operating Profit		20.85%
Other Income/Expense, Net	$691.0K	$330.0K	$15.00K	$89.00K	-$1.306M	$10.00K	-$152.0K	$4.000K	-$26.00K	-$44.00K
YoY Change	109.39%	2100.0%	-83.15%	-106.81%	-13160.0%	-106.58%	-3900.0%	-115.38%	-40.91%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Pretax Income	-$238.7M	$34.77M	-$9.721M	-$68.88M	-$55.35M	-$65.34M	-$65.32M	-$36.21M	-$25.17M	-$12.88M
YoY Change	-786.54%	-457.68%	-85.89%	24.44%	-15.29%	0.03%	80.39%	43.86%	95.42%
Income Tax	-$19.00M	-$609.0K	$15.97M	$0.00	$0.00		$0.00			$0.00
% Of Pretax Income		-1.75%
Net Earnings	-$219.7M	$35.38M	-$25.69M	-$68.88M	-$55.35M	-$65.34M	-$65.32M	-$36.21M	-$25.17M	-$12.88M
YoY Change	-721.02%	-237.73%	-62.71%	24.44%	-15.28%	0.02%	80.39%	43.84%	95.45%
Net Earnings / Revenue	-844.91%	31.94%	-30.19%	-414.99%	-828.97%	-7235.44%	-31556.04%	-447.98%	-418.8%	-423.68%
Basic Earnings Per Share	-$1.66	$0.24	-$0.22	-$0.68	-$1.22
Diluted Earnings Per Share	-$1.66	$0.10	-$0.22	-$0.68	-$1.22	-$2.918M	-$3.197M	-$3.452M	-$3.000M	-$1.580M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Cash & Short-Term Investments	$76.91M	$134.6M	$128.1M	$138.7M	$89.90M	$37.40M	$96.60M	$84.10M	$36.50M	$16.60M
YoY Change	-42.86%	5.11%	-7.67%	54.28%	140.37%	-61.28%	14.86%	130.41%	119.88%
Cash & Equivalents	$76.91M	$106.4M	$114.1M	$138.7M	$89.90M	$37.40M	$70.60M	$58.70M	$32.30M	$16.60M
Short-Term Investments	$0.00	$28.16M	$14.00M			$0.00	$25.90M	$25.50M	$4.100M	$0.00
Other Short-Term Assets	$4.967M	$3.778M	$6.474M	$5.400M	$1.800M	$4.700M	$2.100M	$2.500M	$1.600M	$1.800M
YoY Change	31.47%	-41.64%	19.89%	200.0%	-61.7%	123.81%	-16.0%	56.25%	-11.11%
Inventory
Prepaid Expenses
Receivables	$5.870M	$6.596M	$9.914M	$7.200M	$5.000M		$100.0K	$200.0K	$800.0K	$700.0K
Other Receivables	$2.981M	$3.162M	$0.00	$0.00	$0.00		$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$90.73M	$148.1M	$144.4M	$151.3M	$96.70M	$42.10M	$98.70M	$86.80M	$38.90M	$19.10M
YoY Change	-38.75%	2.56%	-4.53%	56.46%	129.69%	-57.35%	13.71%	123.14%	103.66%
Property, Plant & Equipment	$12.18M	$14.41M	$11.97M	$12.30M	$1.500M	$2.100M	$2.100M	$2.000M	$2.000M	$2.000M
YoY Change	-15.47%	20.38%	-2.67%	720.0%	-28.57%	0.0%	5.0%	0.0%	0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$2.000M	$2.000M	$2.000M
YoY Change	0.0%	0.0%
Other Assets	$1.377M	$1.337M	$1.469M	$1.700M	$1.400M	$300.0K	$300.0K	$400.0K	$1.900M	$1.100M
YoY Change	2.99%	-8.99%	-13.59%	21.43%	366.67%	0.0%	-25.0%	-78.95%	72.73%
Total Long-Term Assets	$214.3M	$17.75M	$15.44M	$14.10M	$2.900M	$2.400M	$2.400M	$2.500M	$3.900M	$3.100M
YoY Change	1107.58%	14.95%	9.5%	386.21%	20.83%	0.0%	-4.0%	-35.9%	25.81%
Total Assets	$305.1M	$165.9M	$159.9M	$165.4M	$99.60M	$44.50M	$101.1M	$89.30M	$42.80M	$22.20M
YoY Change
Accounts Payable	$3.150M	$316.0K	$224.0K	$400.0K	$500.0K	$1.100M	$1.600M	$3.900M	$2.200M	$400.0K
YoY Change	896.84%	41.07%	-44.0%	-20.0%	-54.55%	-31.25%	-58.97%	77.27%	450.0%
Accrued Expenses	$17.74M	$15.69M	$11.58M	$9.100M	$13.90M	$11.60M	$8.500M	$3.900M	$3.000M	$1.600M
YoY Change	13.04%	35.49%	27.27%	-34.53%	19.83%	36.47%	117.95%	30.0%	87.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$8.476M	$5.961M	$0.00	$18.90M	$21.40M	$0.00	$4.100M	$0.00	$2.600M
YoY Change	-100.0%	42.19%		-100.0%	-11.68%		-100.0%		-100.0%
Total Short-Term Liabilities	$68.21M	$25.08M	$72.25M	$81.50M	$34.90M	$35.10M	$11.00M	$13.70M	$7.300M	$9.200M
YoY Change	172.0%	-65.29%	-11.35%	133.52%	-0.57%	219.09%	-19.71%	87.67%	-20.65%
Long-Term Debt	$0.00	$17.79M	$19.67M	$24.80M	$0.00	$0.00	$21.00M	$8.000M	$11.90M	$4.800M
YoY Change	-100.0%	-9.59%	-20.67%			-100.0%	162.5%	-32.77%	147.92%
Other Long-Term Liabilities	$360.6M	$29.20M	$45.44M	$77.10M	$56.20M	$14.80M	$17.30M	$12.70M	$2.700M	$1.900M
YoY Change	1135.2%	-35.75%	-41.07%	37.19%	279.73%	-14.45%	36.22%	370.37%	42.11%
Total Long-Term Liabilities	$360.6M	$46.98M	$65.11M	$101.9M	$56.20M	$14.80M	$38.30M	$20.70M	$14.60M	$6.700M
YoY Change	667.58%	-27.84%	-36.1%	81.32%	279.73%	-61.36%	85.02%	41.78%	117.91%
Total Liabilities	$444.7M	$72.06M	$137.4M	$183.4M	$91.20M	$49.90M	$49.30M	$34.30M	$21.80M	$16.00M
YoY Change	517.11%	-47.54%	-25.1%	101.1%	82.77%	1.22%	43.73%	57.34%	36.25%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	155.1M shares	144.8M shares	114.3M shares	101.2M shares	45.55M shares
Diluted Shares Outstanding	155.1M shares	145.9M shares	114.3M shares	101.2M shares	45.55M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $559.13 Million

About Cartesian Therapeutics, Inc.

Cartesian Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Frederick, Maryland and currently employs 38 full-time employees. The company went IPO on 2016-06-22. Cartesian Therapeutics, Inc. is a clinical-stage company. The firm is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. The company is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. The company is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Industry: Pharmaceutical Preparations Peers: 4D Molecular Therapeutics, Inc. 89bio, Inc. Evelo Biosciences, Inc. LianBio Summit Therapeutics Inc. Voyager Therapeutics, Inc. Vaxxinity, Inc.